CRP and diabetes mellitus: In the monotherapy trial, the small number of patients with diabetes limited data interpretation; however, treatment by subgroup interaction test results were not significant for ACR20 (p = 0.585) or for change from baseline in HAQ-DI (p = 0.719) but were significant for change from baseline in DAS28-CRP (p = 0.003) and CDAI (p = 0.025).